European Journal of Radiology Open (Jan 2022)

A radiologist’s guide to novel anticancer therapies in the era of precision medicine

  • Ali Khader,
  • Rozan Bokhari,
  • Reza Hakimelahi,
  • Christopher Scheirey,
  • Jalil Afnan,
  • Marta Braschi-Amirfarzan,
  • Richard Thomas

Journal volume & issue
Vol. 9
p. 100406

Abstract

Read online

Novel anticancer agents have replaced conventional chemotherapy as first line agents for many cancers, with continued new and expanding indications. Small molecule inhibitors act on cell surface or intracellular targets and prevent the downstream signaling that would otherwise permit tumor growth and spread. Anticancer antibodies can be directed against growth factors or may be immunotherapeutic agents. The latter act by inhibiting mechanisms that cancer cells use to evade the immune system. Hormonal agents act by decreasing levels of hormones that are necessary for the growth of certain cancer cells. Cancer therapy protocols often include novel anticancer agents and conventional chemotherapy used successively or in combination, in order to maximize survival and minimize morbidity. A working knowledge of anti-cancer drug classification will aid the radiologist in assessing response on imaging.

Keywords